N
Google TrendLIONEL MESSI (5000+) — Messi scores twice for Miami in 1st game since Argentina farewell
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:lionel messi5000+sydney sweeney2000+miguel vargas1000+ducks vs flames500+matt rife1000+colin farrell200+emily blunt500+boise state vs fresno state2000+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "Ciltacabtagene Autoleucel" (30 stories)

Top Headline Story

Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial
Lead StoryNaturegeneral
Apr 20

Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1HUjF1MXo4U0lPckpRNWZjclpIMjRmb29kd2xkbXhtOGYteV9SSEI3OTlkcm9WVjJrcUFFaG1oZGRNeTlmNVVWR1dlRWpUc1RzNzV2RTdOamY5czRIVW04?oc=5" target="_blank">Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
5000+16m ago

lionel messi

Messi scores twice for Miami in 1st game since Argentina farewell

Filter stories
2000+16m ago

sydney sweeney

Sydney Sweeney Is Related to Marilyn Monroe

Filter stories
1000+16m ago

miguel vargas

AL Central Notes: Vargas, Tigers Staff, Royals Ballpark

Filter stories
500+16m ago

ducks vs flames

Ducks at Flames projected lineups

Filter stories

Search Results for "Ciltacabtagene Autoleucel"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
Optimizing ciltacabtagene autoleucel outcomes: real-world experience and best practices from a single academic center
Frontiersworld

Optimizing ciltacabtagene autoleucel outcomes: real-world experience and best practices from a single academic center

<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxQekRvak1Ua2NyMTNlMUI4VWEzUWJBQUxsM3dHZ2QwOEFSUFRzQmw4MnZfY3JtSEt3ZklLbm8wNElnOVpuQjNRMGhFT1JUTlQ3WVV2QmNCRFVkSy11cEYzdlQ2blJYRkFFdXVyVVNELUNDU3lIMW9OandBSXYxRFZWZGllVzFOM2hQT1M4TDFB?oc=5" target="_blank">Optimizing ciltacabtagene autoleucel outcomes: real-world experience and best practices from a single academic center</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Where Ciltacabtagene Autoleucel Belongs in Sequencing
CancerNetworkgeneral

Where Ciltacabtagene Autoleucel Belongs in Sequencing

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxQMVkxejMwTGREUllLOXhwZXhuS1dJcG10TnBqVm4tM3JoV1p2ZElhUVJ3U2NIdGc2Z1Rzb1ZvRG4yOFREYTcyUUdUdTJ2TEk2Ynl0MW1ZVlNmMkNjS3JWYXc1OG5WQU9TUldVOHFmUzc2NER1djlmQ2FNMHBqOUcyMDZLTkRNYkpqMzdCcGR5a1hndw?oc=5" target="_blank">Where Ciltacabtagene Autoleucel Belongs in Sequencing</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma
Yahoo Financegeneral

Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma

<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxPQzZEYnk2SmxlcGQ2Rk5nTmVuZTdjdU4tNGU4TmR6NGR4Y0pZVVBpeFdtRGVxOEV1d2Fwck9lZHh3YWk5T0NQcDZIWnpQMlpoNFduQmFyZllTN2IxVG1XOElzMVhpS3F4a3N4ampFelo1VlBtUDctSHRLZkRPY1dHdHJORU5vaVFhQnFpUXpnbzViTHk3MjVYRkFXWGU4UHM0RTJueTU0czRqaWd3WUc4cA?oc=5" target="_blank">Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma</a>  <font color="#6f6f6f">Yahoo Finance</font>

Read Full StoryMore like this
Ciltacabtagene Autoleucel Improves Long-Term Outcomes in Standard-Risk Relapsed/Refractory Multiple Myeloma
HMP Global Learning Networkgeneral

Ciltacabtagene Autoleucel Improves Long-Term Outcomes in Standard-Risk Relapsed/Refractory Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxPZGkyTGlNbUhfN0hxbFBqNlBhWUg5aTRqQUtqOUF6WTBPcWJOcFc1Q29JdUpKWmRRVTVEVm5NTEFEbTRKa1dXRXk4RHZtNHBjX0ktaTZyMUlSR1RLU3BpaUNQak02UDB5cy1PeDR4UjEyZm51NWdKUDhMZFFjYVRoRFd1R3oybFExTmpzeTRFS0Y1SXYxOGZfOFM2Y2lEZGJuS2ZON1FmOHRqTzk2ZmRXdVZEbVBPaVV2SDBYZ3NoV0pSZw?oc=5" target="_blank">Ciltacabtagene Autoleucel Improves Long-Term Outcomes in Standard-Risk Relapsed/Refractory Multiple Myeloma</a>  <font color="#6f6f6f">HMP Global Learning Network</font>

Read Full StoryMore like this
Cilta-Cel Shows Long-Term Treatment-Free Remissions in Lenalidomide-Refractory Myeloma
OncLivegeneral

Cilta-Cel Shows Long-Term Treatment-Free Remissions in Lenalidomide-Refractory Myeloma

<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxNWnBZMUZOTHJtanRHMUQ3V0JjMG43eEhQNGJTYTVxY0h4ZDU3cU9EUmNkdXFGRU5PeG1oSVdIaXJzLTRpcl9nTC1mQV8wNHRpOUNCQklzOHNFNVE3cU9SY0lIcnVreTBDX0c0SVNnSUFUa0FUSmN1STZ3Tkp1NVVtZ1U5RXVsb0lzRm02SndGc25qTXRMZEpBNnJPTXk4REVIUTBISWRXVk5PcER1RFMydzlDUjlUdw?oc=5" target="_blank">Cilta-Cel Shows Long-Term Treatment-Free Remissions in Lenalidomide-Refractory Myeloma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Real-World Cilta-Cel Outcomes Extend Beyond Trial Populations in R/R Myeloma
Targeted Oncologyworld

Real-World Cilta-Cel Outcomes Extend Beyond Trial Populations in R/R Myeloma

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxPY0hPTDZkckVqX3pMcU5uZDl3bW5PLVhGYzhGTzJDN0ZlTnR1VGdqUG9mTmxwdzVBNW5URktOb1JCcE1iWGpKNklDVXBZc0NTRU9kb3BNc3VnRjBYR1I3NVIyZmtJZHVveWczYmZUVEx3SjBVZDRjN1F0Z1EySDhtNW5qWnNFYzNSRnQ4Y1o3V0dwUjZnMUJuZGV2QXQzQzRYc0hsOVJuVTZpLTNTOFE?oc=5" target="_blank">Real-World Cilta-Cel Outcomes Extend Beyond Trial Populations in R/R Myeloma</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
Updated Analysis of CARTITUDE-4: Ciltacabtagene Autoleucel in Lenalidomide-Refractory Multiple Myeloma
The ASCO Postgeneral

Updated Analysis of CARTITUDE-4: Ciltacabtagene Autoleucel in Lenalidomide-Refractory Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxOSUlKZ29abnBNdnM4VG5RaHFrNC03ZnRtZTM5Ykd4cHgyWmpxLWl3Mk9Tb2hvOFBIZm5QN2NkNGpfdktDUVVrYTh5amdPUDdjWjE5SjhKMEpRTF9seU1tZGkzZlM4R255a0V0dGFXZjk2VlV3bGd0ZURSbFRNN1BOSEpVN21JUzFFd1NEcWxlbGtnQXJSZW9YaTFMX3haOWtxSDB1MFNUSWoxUzktUzJRZXJJLXFncGN1ckljTXlXbDJVVzg?oc=5" target="_blank">Updated Analysis of CARTITUDE-4: Ciltacabtagene Autoleucel in Lenalidomide-Refractory Multiple Myeloma</a>  <font color="#6f6f6f">The ASCO Post</font>

Read Full StoryMore like this
CARVYKTI achieves five-year treatment-free remission in 50% of early-line myeloma patients
The Clinical Trial Vanguardgeneral

CARVYKTI achieves five-year treatment-free remission in 50% of early-line myeloma patients

<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxPa2xneWoxN3lHMHBTSElyYkRpaVdIRnY2eVItZ3Y1bHBFRWFpRl9JdVNJZ1pHUVRFN2cxeGNydXJpQTVWUC1MSFRqZ1NaSGU4M0hDTUJwYzNiZllFVEtLUkJZWUZ2RS15Sm0zdUUzQWV0cmdjRTRwRXlITkZwcll2N2pVODRMekJuUFVkdkJqbEZ3VmducGRfS0MzSzBXSTRyQ1l6OEoxYzZYclNiYTNybkpZMUJaUlBzOXZodlpCWF9aLU9PalgxcEdBTllWUQ?oc=5" target="_blank">CARVYKTI achieves five-year treatment-free remission in 50% of early-line myeloma patients</a>  <font color="#6f6f6f">The Clinical Trial Vanguard</font>

Read Full StoryMore like this
Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma: The CAR-PRISM Phase 2 Trial
CancerNetworkgeneral

Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma: The CAR-PRISM Phase 2 Trial

<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxOX0EzdXJMY0pITHNCS28xTHhkM1hVblJnS3dIMFJoakNIVmJucGlPQ1g5MVplUnJaWDNfZDRfdC1VbXdlazZKS05MZDdnODFWemVIOEVzeVZxeDl1bFlLcWduQkZxUHZzX053b3dkRnktWVNiRm1ySXdXUDRqVHZSbDM5SzYybHhETGxRYmlKOE4wa0NEQlBxQkxYTUxEQkl6ZWZvNWdKdHFWYUhwM3E4R0ZLd3hRVm1FUHh4YkhvMTRfYTljN3RZbA?oc=5" target="_blank">Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma: The CAR-PRISM Phase 2 Trial</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Clinical course, risk factors and mitigating strategies for Immune effector cell-associated late onset neurotoxicities after ciltacabtagene autoleucel CAR-T in multiple myeloma | Blood Cancer Journal
Natureworld

Clinical course, risk factors and mitigating strategies for Immune effector cell-associated late onset neurotoxicities after ciltacabtagene autoleucel CAR-T in multiple myeloma | Blood Cancer Journal

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1la0F6ZFlrQTR5bmplN3FNVWJzaTJGdXBxbmYtTk5WZ1JobFZycWZhc3lxMllEVE1vN1NNOG5KY2U1VEF5TkpqSzRBMVJIeTk3TzdtSGFsZTlPQjllQnFz?oc=5" target="_blank">Clinical course, risk factors and mitigating strategies for Immune effector cell-associated late onset neurotoxicities after ciltacabtagene autoleucel CAR-T in multiple myeloma | Blood Cancer Journal</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Reversible cerebral vasoconstriction syndrome following ciltacabtagene autoleucel therapy for relapsed multiple myeloma: a case report
Frontiersgeneral

Reversible cerebral vasoconstriction syndrome following ciltacabtagene autoleucel therapy for relapsed multiple myeloma: a case report

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxONVZaVTZhUGpUQ183TDRRbnpUbnZuUUNVem1ENk9FcXBjU0UwTDhzLXFOdGF2S2hmRDBRQXBpdlBfeTNZVEhMV0l4YzJjbEE1TmNSVFNDQk4zTWZxdFFPSDVsZ3VNY3hiNXBwb3B4ck14V3hTTHFWSzUwbUpiX1QyRVNEQjhMMzk0a19rMGNXX3pRQQ?oc=5" target="_blank">Reversible cerebral vasoconstriction syndrome following ciltacabtagene autoleucel therapy for relapsed multiple myeloma: a case report</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Cilta-Cel Generates 100% ORR, MRD-Negativity Rate in High-Risk Smoldering Myeloma
OncLivegeneral

Cilta-Cel Generates 100% ORR, MRD-Negativity Rate in High-Risk Smoldering Myeloma

<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxQbVlTNUl1TlQxMm1pY0NrRGt4cG4yN3NYNVVNZXJkdUZ3Z011ZFF3X18xNVdZQzA1SmUxVjM5dFlJYUpoZ1lOR2tHX3A3V01MMEF2MmhnUE14MkZrSWduenNDeFIwLWxlUlc3aDY4QW9HVHlfTVFDTVB0OENGZXZYSk1pYnd1NVIwTDhLc21fMldYMWMzNzZwdHhZalgtenN4cmxBNUpNMjhQUmR1?oc=5" target="_blank">Cilta-Cel Generates 100% ORR, MRD-Negativity Rate in High-Risk Smoldering Myeloma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Bridging Outcome, ALC Linked to Parkinsonism With Cilta-Cel in Multiple Myeloma
Targeted Oncologygeneral

Bridging Outcome, ALC Linked to Parkinsonism With Cilta-Cel in Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxOSGVVWko4X0J0UlBxSUxZQ2lpX1Jza1lQMVdfenBFaDhzcTlOVWRtaTY0M1dCTzdCTk9JaTY3MkdxMGhCcW1uYXdQaEZFWjZsbXkzVk5MM2owbVNRVW1HTUhIQjFyUTN1Wm5FRDdYRE5NdEFqbFd1c1ZLd2ZrVGdBN0FKaGJaU1hjV0QtWXN3YkVXZDc4T3dzMGNFV2lfZw?oc=5" target="_blank">Bridging Outcome, ALC Linked to Parkinsonism With Cilta-Cel in Multiple Myeloma</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
Day 28 Discharge and Transition to Shared Community Care
CancerNetworkworld

Day 28 Discharge and Transition to Shared Community Care

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxPZlhTTzk5TU43NEE4bzQtVUN3MUVPd3FZSDFsM0NvUTFUYTN2TThDUXJTOVZMQ05FdnlWekM4WUZ2cndCcmlkM3dfaHNJUlNFd0ZaZXBnSlB3M1I1MkZzUG50ZGJPT3ZZTW1ESWFrYTZVQTZRMHB5SUZaY1dfa1NHWjBUbVpjTW1hY29JMnpZNXZNSG5CSVE?oc=5" target="_blank">Day 28 Discharge and Transition to Shared Community Care</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Clinical experience with cranial nerve palsy in patients infused with ciltacabtagene autoleucel for the treatment of relapsed/refractory MM in CARTITUDE-1, -2, and -4 | Blood Cancer Journal
Naturegeneral

Clinical experience with cranial nerve palsy in patients infused with ciltacabtagene autoleucel for the treatment of relapsed/refractory MM in CARTITUDE-1, -2, and -4 | Blood Cancer Journal

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1wdE5kVFJwUFI3SFJhdGExbTZURGpFTWJyN0hpbVptaTUza3cxWFN0dGJZeGd2WTZlUU1WMGJkSTJnM1FsQ3JncHpSOXNQaFh1Zm5DbjhaWVZRVjRsNmtB?oc=5" target="_blank">Clinical experience with cranial nerve palsy in patients infused with ciltacabtagene autoleucel for the treatment of relapsed/refractory MM in CARTITUDE-1, -2, and -4 | Blood Cancer Journal</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Real-World Tolerability of Cilta-Cel Aligns With Multiple Myeloma Trials
Targeted Oncologyworld

Real-World Tolerability of Cilta-Cel Aligns With Multiple Myeloma Trials

<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxNZ0RxZ083YXpxVlBHeU5YblVhd1RxNDFlOE5nd1lxZ2I1LWRBdjNmRkpSc1c0MGRGM3gtNHpmUXNHQW5Zd3hhbmstT0tqck0ybm9jbmVlVGpyREhZWFdXVG9ZcEU3Y2hfbUVtWEpSek14RUVmT1A2UUcxalZ2ZWlma1UwbmsyUFZadnk2U09JRXE2NU1aeFFWZXAwZDVab3dldjk4S1Q5Y20?oc=5" target="_blank">Real-World Tolerability of Cilta-Cel Aligns With Multiple Myeloma Trials</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
Recognizing Delayed Neurotoxicity and Immune Effector Cell Enterocolitis
CancerNetworkworld

Recognizing Delayed Neurotoxicity and Immune Effector Cell Enterocolitis

<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxOSm5yNGFMY2x5eHZOUnNzeVF6SmRTVk9qUGJzNVBBVDFHTTltdUNSNjVHdTRIZGQxRkJTWDlvLVNhQ0lRU3dMUGVEM3VkeGplQVIzRldnOXc4MTFnODV5aW9ndmlSR2tTTWt3S3NaaWI4WDE0dlBKZksyb3ZfUEdLaU1Ob2xvN1VwTVFXZFFBX3cwbDkyWXNQM2pZZXlhQ0NtdVhLSkpsNjl2WlE?oc=5" target="_blank">Recognizing Delayed Neurotoxicity and Immune Effector Cell Enterocolitis</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Phase 2 Outcomes Show Potential of Cilta-Cel in Smoldering Myeloma
Targeted Oncologygeneral

Phase 2 Outcomes Show Potential of Cilta-Cel in Smoldering Myeloma

<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxOaEV2b0dtOG1ZRjhsTC16UmF0cmg5NzhkTFNRQTJzbTVFNFZ2bGhtUjRLQmZkSlJYYWpUeTRxT2NWbmhzYkdtTXpXOVhWMUxZdjVMU3loa09KX01ZUjdpTC01aGJ5OHlTREg2YUtzSjlTQU9vekNGNndkeEJQWktXbWtxSzJFamFDbUhrYjcxYy1DTUwtaXRwdG5UMTZQQ1B3?oc=5" target="_blank">Phase 2 Outcomes Show Potential of Cilta-Cel in Smoldering Myeloma</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
Relapsed/Refractory Multiple Myeloma: CARTITUDE-4 and the Evolving Role of BCMA CAR T-Cell Therapy
CancerNetworkgeneral

Relapsed/Refractory Multiple Myeloma: CARTITUDE-4 and the Evolving Role of BCMA CAR T-Cell Therapy

<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxQUklDdHNRbC1IWXNHcTFhUnJWMXZJSWRYNHpGNWZsY2JyNXB2bjl6TnR5VzdlTm9sN1R2YUE1VXpZTGo3NHYzTlB6d1dxYVVGVi1jTUdNS3VKU3U4empGc1FfVVdtTVRkT1YweUluc2RPZ1VVU0lCNUlKMmdJakpRZWlQS1lmNEE3Skk3N25naUYxM1JwSVppa2FDNUJEeC1UUUxfenc4WVd2VFc0OVJkcVgtZGlKdVdIVjYzcUdXalE5cE5vNjh0VEU2NlI?oc=5" target="_blank">Relapsed/Refractory Multiple Myeloma: CARTITUDE-4 and the Evolving Role of BCMA CAR T-Cell Therapy</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Cilta-Cel Yields 100% MRD Negativity in High-Risk Smoldering Myeloma
Targeted Oncologygeneral

Cilta-Cel Yields 100% MRD Negativity in High-Risk Smoldering Myeloma

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxQck5rOTg2eEVfWmZ0UnFIcVJCT0tOMXBrWUdnMjJmSEdaRUdtTnR2ay1FRUczb20tWDNJcmRlZkxETjVuVFNVY01ZOEZqZDdUVGgyckEtMHVIcl9YUXh1Ry10algyXy1mTWs2X3NRSnppOEV5dzJkLTREOWRUcTUwSlE5OUNTR1F5YkhrRUZRcEp4R255UU1LT3hiNVZWLVNkVlE?oc=5" target="_blank">Cilta-Cel Yields 100% MRD Negativity in High-Risk Smoldering Myeloma</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
Carvykti sustains five-year remissions in half of early-line relapsed myeloma patients
AllScitech

Carvykti sustains five-year remissions in half of early-line relapsed myeloma patients

<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxQNEtSMmtsVkE4S3VNZHF1c2w0QVlHTWUxMUl3RzlYMEpQUGVMcGg4amhoSzVBeE1SamF2aGFuU1FOQnhpWVRsbHlhSFF0aWw2T2RHc2t6Ym4zUnpnRGNBSEFwSlk1OFdVWmNnbjFWUFRScktTZDNfT3ZmOE50UkRVbktQRDJKODNIQ3JoNjN1cw?oc=5" target="_blank">Carvykti sustains five-year remissions in half of early-line relapsed myeloma patients</a>  <font color="#6f6f6f">AllSci</font>

Read Full StoryMore like this
Anito-Cel Delivers Durable Responses With Low Neurotoxicity in RRMM
Targeted Oncologygeneral

Anito-Cel Delivers Durable Responses With Low Neurotoxicity in RRMM

<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxQWk9KYnVtQzBiV25uRGszQkczcVFuZlR5eXhlZUFzUXVoc0FLcXVldFdCNlhHQWMwbDZlZEstVXluZnMyLVVqcHRmV002QXRxRVVxNG5ISzFNWWh3WlFROW93TWNZZzdtV29FUEk4M1RiZkZET2hLaVFYWlp3d3ZacEhLMHBWSUJfRnBwVjBvWU1STFdZdU9lZUJsRQ?oc=5" target="_blank">Anito-Cel Delivers Durable Responses With Low Neurotoxicity in RRMM</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
Single infusion of CARVYKTI®▼ (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma
The Manila Timesgeneral

Single infusion of CARVYKTI®▼ (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma

<a href="https://news.google.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?oc=5" target="_blank">Single infusion of CARVYKTI®▼ (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma</a>  <font color="#6f6f6f">The Manila Times</font>

Read Full StoryMore like this
CARTITUDE-4 Analysis Shows Bridging Therapy Response Predicts Cilta-Cel Benefit in Lenalidomide-Refractory Myeloma
OncLivegeneral

CARTITUDE-4 Analysis Shows Bridging Therapy Response Predicts Cilta-Cel Benefit in Lenalidomide-Refractory Myeloma

<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxNQTNyZWZPY2lNZ1FZTF9FNWhpbUpxM3VSODJVSFZGNGhjYVd1TWRMLWpLZFpWTGxhZVVnMDdMelNsVUVkT3BlZEd0TV91MVZHOVVhSW84Z0VkVXNyNC1oY1dDdFRlZlBXN3FKQmJfM3k2Si1Yb05CME1jQkZHcHRyNTBDa195ZV9PbHdDWnNWNmVPZEl3blZSOEZ4OVpJaU1hZkd3YVVWVzNWTFNqSGhVQTJOMjNlNHU4Ukctc0Q1M3NtdEY2dXh2YnBVcUZvM0hNTk1WbmxqZWRRTDA?oc=5" target="_blank">CARTITUDE-4 Analysis Shows Bridging Therapy Response Predicts Cilta-Cel Benefit in Lenalidomide-Refractory Myeloma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Long-Term CARTITUDE-4 Data Point to Potential Cure Fraction With Cilta-Cel in Standard-Risk R/R Myeloma
OncLivegeneral

Long-Term CARTITUDE-4 Data Point to Potential Cure Fraction With Cilta-Cel in Standard-Risk R/R Myeloma

<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxPOFpXSkJuUGZGYVg4dWs2RFdTSWcxdVVOQ3A3dkhWTzg0WTJBWE95OFN0NFVMaEJGS1k0R2dVNWc0N0ltMVFVUU5WMnU4R0JzMzE4NXNTQXJ2MDlnWmwtbXIwRlBfSHQzbWdxdFFsNjU3UVg4VWE1SktLZFZKbzVhSm5LRkRyaEJDd0txazJtTnI3WFg3SkMxN3NfT3FYdUtaQW14cmdrUWtYY1RpakJPZGNFLVFuWGRqWENTaGpKdmpwWlN1UUV5QUUxZkM?oc=5" target="_blank">Long-Term CARTITUDE-4 Data Point to Potential Cure Fraction With Cilta-Cel in Standard-Risk R/R Myeloma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Pharmacokinetics of CAR T cells in multiple myeloma – the good, the bad, and the ugly
Naturegeneral

Pharmacokinetics of CAR T cells in multiple myeloma – the good, the bad, and the ugly

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFB3dXhHeFB5OVl1TndBX3kydWM1VDhUOUQzNjc2NlV3bUhxWURqakYxelhmYS1nZGdpWldOZDFwNVhXRnhRaFhvUmIwT1FPaUVvZldlOWtsOWpDUThqX2Zv?oc=5" target="_blank">Pharmacokinetics of CAR T cells in multiple myeloma – the good, the bad, and the ugly</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Early Use of Cilta-Cel Is Linked to Stronger Outcomes Due to Immune Fitness in R/R Myeloma
OncLiveworld

Early Use of Cilta-Cel Is Linked to Stronger Outcomes Due to Immune Fitness in R/R Myeloma

<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxQdEhSWXRhdlJsSHIzNHFpdWhpUzVCNFNHV2pqcmhXZm5zUXhibjl0S2hpMlF3XzZXc1FKaHR0RHBSNG1mdkdPZEVVc0RnVEJNU1plUkZJZ1ZKeG5DQ1VYUGV4cEZNNVlnMF9uUUFJai1VMzBxaWVSMnFCXzhpVDZ6ZE41OU1jaTBtblE2M0xtWkMwdWU4M0M3b1ZSMXI0NEtPY3dKcE9Kbm4xMjg0aHhNa05zTlRGcDdBRTBF?oc=5" target="_blank">Early Use of Cilta-Cel Is Linked to Stronger Outcomes Due to Immune Fitness in R/R Myeloma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Legend Biotech Reports Five-Year CARTITUDE-2 Data Showing Durable Treatment-Free Remission With CARVYKTI in Earlier-Line Multiple Myeloma
Quiver Quantitativetech

Legend Biotech Reports Five-Year CARTITUDE-2 Data Showing Durable Treatment-Free Remission With CARVYKTI in Earlier-Line Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMi_wFBVV95cUxNY3l6YmFaUlk3V1BZd3ZOX2FFM29zb3ZhYjh0ZnhmWE5aSklLZUV0M0FNQlJMVEFuSVZOTkw4dDU0MUdKTVFPa21KZVFCT3NZRWxZZlkwU2JVX0NWN1U0emthOW9Ock9QYldNY2hBWVpfcVhPNWRSRGlYd0JYcklhQ2llX3BNX2JxUG9wak5pYUpTaVhXMWs4My1zOGE3Ym9pc2tWYUVfMEJSUG1aOWlVZ0Y3RUZUV3psdFZQMTBpZjZRbWtaWFBYNG1kWFlDSF9EU2xyeWNkUkFtTzZBVDRWenpXTElzVTVuMFpHOW5XVmc2SjVEVmJhczVlUlB4NDg?oc=5" target="_blank">Legend Biotech Reports Five-Year CARTITUDE-2 Data Showing Durable Treatment-Free Remission With CARVYKTI in Earlier-Line Multiple Myeloma</a>  <font color="#6f6f6f">Quiver Quantitative</font>

Read Full StoryMore like this
Single CAR T infusion shows strong response in smoldering multiple myeloma patients
News-Medicalgeneral

Single CAR T infusion shows strong response in smoldering multiple myeloma patients

<a href="https://news.google.com/rss/articles/CBMi3wFBVV95cUxOd3Q5Nm1fMWxJQV9vempKQXFLQ0FveWhnaWgyQ2ZQS3lNUExZUWg5WTBTWDB5cmR5TUJObl9pc3RJcVp3M1pLM0NmZnphQlR4aDVVaXdqeEgzcE1EMFBhXzdHMzcwalBvRmJfbkRCcjBLVHZvLUhmZzRONlpfQ0VCUHU1U2QxUlJvLTF4NG1tNWpZbS1hZVpZWFg3M3E0RHQ1OVppU0d3Z0dnVG9vRWJheW5ULVJLZC1jOU1oM19oVEU5M0dTWGJYTFVENTloN3lBNEE2WWpHLW9JYTlwb05r?oc=5" target="_blank">Single CAR T infusion shows strong response in smoldering multiple myeloma patients</a>  <font color="#6f6f6f">News-Medical</font>

Read Full StoryMore like this
"Ciltacabtagene Autoleucel" — Live Google News Trends & Headlines